Haya Almuzirai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Haya Almuzirai has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Amos Buh
Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada
1 shared publication - Ayub Akbari
Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
1 shared publication - Babak Rashidi
Division of General Internal Medicine, Department of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada
1 shared publication - Christopher R. McCudden
University of Ottawa, Ottawa, ON, Canada
1 shared publication - Elmira Amooei
Department of Systems and Computer Engineering, Carleton University, Ottawa, ON K1S 5B6, Canada
1 shared publication - Gregory L. Hundemer
University of Ottawa
1 shared publication
Latest Publications
- Open Access
- 31 March 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (4) , 430
Analytical Models to Optimize Tacrolimus Dosing in Solid Organ Transplantation: A Systematic Review
Background: Tacrolimus dose optimization remains challenging due to its narrow therapeutic range and multiple influencing variables. This systematic review aimed to identify effective analytical modeling techniques for optimal tacrolimus dose prediction in solid organ transplant recipients. Methods: Two independent researchers conducted a comprehensive review of studies examining analytical models that optimize tacrolimus dosing, searching Medline, Scopus, Embase, Web of Science, and PubMed. Results: In total, 115 studies met the inclusion criteria. Pharmacokinetic models (74 studies), particularly two-compartment with Bayesian forecasting, were most frequently used. Machine learning (ML) approaches, with increasing adoption, have demonstrated promising improved predictive accuracy. Key predictive variables included CYP3A5 genotype, hematocrit levels, post-operative days, and weight; however, the significance of genomic features seemed to diminish progressively as therapeutic drug monitoring calibrates dosing in the months following post-transplant. Only ten studies performed external validation, and none incorporated adherence data or predicted long-term graft outcomes. Conclusions: Clinical deployment of predictive models for tacrolimus dosing remains uncommon. In research, pharmacokinetic models remain prevalent, with ML approaches showing early incremental promise. Limited external validation raises generalizability concerns. Future research should prioritize outcome-based evaluation metrics rather than error metrics.
- 31 March 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (4) , 430
Open AccessAnalytical Models to Optimize Tacrolimus Dosing in Solid Organ Transplantation: A Systematic Review
Background: Tacrolimus dose optimization remains challenging due to its narrow therapeutic range and multiple influencing variables. This systematic review aimed to identify effective analytical modeling techniques for optimal tacrolimus dose prediction in solid organ transplant recipients. Methods: Two independent researchers conducted a comprehensive review of studies examining analytical models that optimize tacrolimus dosing, searching Medline, Scopus, Embase, Web of Science, and PubMed. Results: In total, 115 studies met the inclusion criteria. Pharmacokinetic models (74 studies), particularly two-compartment with Bayesian forecasting, were most frequently used. Machine learning (ML) approaches, with increasing adoption, have demonstrated promising improved predictive accuracy. Key predictive variables included CYP3A5 genotype, hematocrit levels, post-operative days, and weight; however, the significance of genomic features seemed to diminish progressively as therapeutic drug monitoring calibrates dosing in the months following post-transplant. Only ten studies performed external validation, and none incorporated adherence data or predicted long-term graft outcomes. Conclusions: Clinical deployment of predictive models for tacrolimus dosing remains uncommon. In research, pharmacokinetic models remain prevalent, with ML approaches showing early incremental promise. Limited external validation raises generalizability concerns. Future research should prioritize outcome-based evaluation metrics rather than error metrics.